SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as investors react to recent institutional buying, including a significant boost in Goldman Sachs' position, fueling speculation about future government contracts. The community is actively discussing potential catalysts, such as anticipated rate cuts and the company's expansion into commercial contracts, with some drawing parallels to Palantir's growth trajectory. Many are focused on technical levels, anticipating a breakout above key resistance points and a potential short squeeze.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as community members discuss the potential impact of Starbucks' CEO comments about Luckin's innovation and speed.  Traders are eyeing the $40 mark, with some anticipating a breakout and others expressing frustration over perceived price manipulation.  Overall sentiment seems bullish, fueled by expansion news and speculation around relisting.

The vision behind $DAIO's Reward System is simple. Those that hold and buy dips should be rewarded over jeets or buy pressure sellers. In theory if everyone held together the coin would go up right?  Sadly that is not the case but the DAIO feels those that are loyal to a coin shall be rewarded. First use case is $DAIO and the agents that follow. Phase II will unlock it's second use case, the Solana blockchain.

Decentralized AI Organization

Decentralized AI Organization ($DAIO.X) is trending as users highlight its potential as an early-stage AI blockchain play. Community members are drawn to its microcap status, anticipating substantial upside and advocating for strong, early adoption. The token's availability on Phantom is also being noted as a catalyst.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Quoin Pharmaceuticals is trending amid community speculation around a potential short squeeze and discussions on its low float. Some traders are pointing to positive clinical data and patent filings as potential catalysts. Others caution about the company's history and potential for reverse stock splits.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is surging amidst news of regulatory approval for its Oxford Ionics acquisition, sparking discussions about the company's growth potential and future role in the quantum computing landscape. Community members are actively debating the stock's valuation, comparing it to competitors, and anticipating further catalysts such as the Quantum World Congress and potential government contracts. Bullish sentiment appears to be fueled by analyst upgrades and the broader interest in quantum computing, while some express concerns about valuation and profitability.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE.X is trending as the community speculates on potential price movements and whether it can regain previous highs. Some traders express frustration with volatility, while others see current dips as buying opportunities, signaling divided sentiment. The coin's future performance within the broader meme coin market is a key point of discussion.

RCI Hospitality Holdings, Inc. engages in the provision of live adult entertainment and dining experiences. It operates through the following segments: Nightclubs and Bombshells. The Nightclubs segment includes adult entertainment. The Bombshells segment involves the operation of restaurants and bars. The company was founded by Robert L. Watters in 1983 and is headquartered in Houston, TX.

RCI Hospitality Holdings Inc

RCI Hospitality (RICK) is trending due to an indictment against top executives for alleged tax fraud and bribery, sparking community concern about the company's future and potential impact on liquor licenses; despite the negative news, some investors are seeing this as a buying opportunity, citing the underlying real estate value and strong cash flow, while others question management's capital allocation strategy amid the broader context of recessionary indicators.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential for further growth, with some eyeing a move towards higher price targets. Bullish sentiment is fueled by news of institutional interest and significant treasury acquisitions. Attention is also focused on various Solana-based tokens and meme coins, with users sharing potential plays.

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

Turbo Energy (TURB) is trending due to a recently announced \$53 million contract for energy storage projects, driving significant pre-market gains and high trading volume. Community chatter highlights excitement around the stock's potential for a substantial run, drawing comparisons to other low-float stocks that have experienced similar surges. Traders are actively discussing entry points and strategies to capitalize on the stock's momentum, while also watching for potential pullbacks.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amid discussions about Elon Musk's recent stock purchase and its potential impact on his compensation package and the company's future. Community members are debating the stock's valuation, potential for growth in areas like AI and robotics, and the influence of broader market factors like interest rate decisions, while some highlight a new partnership with Uber Freight utilizing Tesla Semis.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of GT Biopharma, Inc. surged more than 21% on Tuesday before slipping after-hours as investors reacted to the company's unexpected shift in its financing strategy.&nbsp;The announcement sent 24-hour message volume on Stocktwits skyrocketing by 18,700%, marking the highest spike among biotech stocks, with trading volume more than doubling from its daily average.The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.&nbsp;The filing had not yet been declared effective, and no securities had been sold under the proposed offering.&nbsp;Instead, GT Biopharma opted for a direct warrant exercise agreement, securing immediate funds while offering new unregistered warrants to investors.Under the new arrangement, the company entered into definitive agreements to exercise existing warrants to purchase 302,069 shares of common stock, with an exercise price of $4.35 per share.&nbsp;The move is expected to generate approximately $700,000 in gross proceeds before deducting placement agent fees and offering expenses.The offering is anticipated to close by Thursday, with proceeds earmarked for working capital and general corporate purposes.On Stocktwits, retail investors' reactions were mostly positive to the company's financing shift.&nbsp;One user described the move as "going in the right direction."&nbsp;<stembedurl>https://stocktwits.com/Rassy40/message/605686808</stembedurl>Another pointed out that short sellers had expected dilution due to the S-1 registration, but they may now be forced to cover with the offering canceled.&nbsp;<stembedurl>https://stocktwits.com/Annet_why_net/message/605691704</stembedurl>However, some traders indicated they were still waiting for a more attractive entry point.Short interest on GTBP shares has jumped from 0.6% at the start of the year to 8.8% at the end of last week, per Koyfin data.Beyond the financing development, Roth MKM remains optimistic about GT Biopharma's clinical pipeline.&nbsp;The research firm expects the company to release initial data later this year from its Phase 1 trial evaluating GTB-3650, its therapy targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome.GT Biopharma ended 2024 with approximately $4 million in cash, which Roth MKM estimates is sufficient to fund operations into the second quarter of this year.&nbsp;The research firm maintained a 'Buy' rating on the stock, with an $11 price target, implying a potential fivefold increase from current levels.The company's stock has lost more than 17% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak

The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.

Equity

The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.


Recap: GT Biopharma Q4 Earnings

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...

GT Biopharma trading halted, news pending

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GT Biopharma announces 1-for-30 reverse stock split

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the Company ), a clinical stage immuno-oncology company focused on developing innovative therapeutics...

Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 150.2%

GT Biopharma, Inc. (NASDAQ:GTBP  Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 58,800...

GT Biopharma (NASDAQ:GTBP) & PaxMedica (NASDAQ:PXMD) Critical Survey

GT Biopharma (NASDAQ:GTBP  Get Free Report) and PaxMedica (NASDAQ:PXMD  Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the...

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

GT Biopharma Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

GTBP
GT Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GTBP News

GTBP GT Biopharma Inc